Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 12 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Avelumab for gastric and gastroesophageal junction adenocarcinoma – third line	Avelumab (Bavencio; MSB-0010718C)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2017	View \| Download
Avelumab for gastric or gastro-oesophageal junction cancer - first line maintenance	Avelumab (Bavencio; MSB-0010718C)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Nivolumab in addition to chemotherapy for advanced gastric cancer – first line	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastric cancer	Gastrointestinal Cancer	2018	View \| Download
Nivolumab in combination with ipilimumab for gastric or gastroesophageal junction cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastric cancer	Gastrointestinal Cancer	2021	View \| Download
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line	Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2017	View \| Download
Pembrolizumab in addition to chemotherapy for perioperative treatment of gastric or gastro-oesophageal junction adenocarcinoma	FLOT , Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Pembrolizumab in addition to trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – First-line	Pembrolizumab (Keytruda; MK-3475) , Trastuzumab (Herceptin; RG-597)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2019	View \| Download
Pembrolizumab plus chemotherapy for the treatment of gastric cancer or gastro-oesophageal junction cancer – First Line	Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2021	View \| Download
Rivoceranib for locally advanced or metastatic gastric or gastro-oesophageal junction cancer - after two or more therapies	Rivoceranib (Apatinib; YN968D1)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2020	View \| Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma	Chemotherapy , Tislelizumab (BGB-A317; BGBA-317)	Gastric cancer , Gastro-oesophageal junction adenocarcinoma	Gastrointestinal Cancer	2022	View \| Download